In silico thrombectomy trials for acute ischemic stroke

Claire Miller, Praneeta Konduri, Sara Bridio, Giulia Luraghi, Nerea Arrarte Terreros, Nikki Boodt, Noor Samuels, Jose F. Rodriguez Matas, Francesco Migliavacca, Hester Lingsma, Aad van der Lugt, Yvo Roos, Diederik Dippel, Henk Marquering, Charles Majoie, Alfons Hoekstra*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
62 Downloads (Pure)


Background and objective: In silico trials aim to speed up the introduction of new devices in clinical practice by testing device design and performance in different patient scenarios and improving patient stratification for optimizing clinical trials. In this paper, we demonstrate an in silico trial framework for thrombectomy treatment of acute ischemic stroke and apply this framework to compare treatment outcomes in different subpopulations and with different thrombectomy stent-retriever devices. We employ a novel surrogate thrombectomy model to evaluate the thrombectomy success in the in silico trial.

Methods:The surrogate thrombectomy model, built using data from a fine-grained finite-element model, is a device-specific binary classifier (logistic regression), to estimate the probability of successful recanalization, the outcome of interest. We incorporate this surrogate model within our previously developed in silico trial framework and demonstrate its use with three examples of in silico clinical trials. The first trial is a validation trial for the surrogate thrombectomy model. We then present two exploratory trials: one evaluating the performance of a commercially available device based on the fibrin composition in the occluding thrombus and one comparing the performance of two commercially available stent retrievers.

Results: The Validation Trial showed the surrogate thrombectomy model was able to reproduce a similar recanalization rate as the real-life MR CLEAN trial (p=0.6). Results from the first exploratory trial showed that the chance of successful thrombectomy increases with higher blood cell concentrations in the thrombi, which is in line with observations from clinical data. The second exploratory trial showed improved recanalization success with a newer stent retriever device; however, these results require further investigation as the surrogate model for the newer stent retriever device has not yet been validated.

Conclusions: In this novel study, we have shown that in silico trials have the potential to help inform medical device developers on the performance of a new device and may also be used to select populations of interest for a clinical trial. This would reduce the time and costs involved in device development and traditional clinical trials.

Original languageEnglish
Article number107244
JournalComputer Methods and Programs in Biomedicine
Early online date15 Nov 2022
Publication statusPublished - Jan 2023

Bibliographical note

Funding Information: This project (INSIST; ) has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 777072.

Publisher Copyright: © 2022 The Author(s)


Dive into the research topics of 'In silico thrombectomy trials for acute ischemic stroke'. Together they form a unique fingerprint.

Cite this